Loading...
CC logo

The Chemours CompanyNYSE:CC Stock Report

Market Cap US$2.5b
Share Price
US$17.53
n/a
1Y24.3%
7D-2.7%
Portfolio Value
​
View

The Chemours Company

NYSE:CC Stock Report

Market Cap: US$2.5b

Chemours (CC) Stock Overview

Provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. More details

CC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends2/6

Rewards

Trading at 63.7% below our estimate of its fair value

Earnings are forecast to grow 115.5% per year

Trading at good value compared to peers and industry

Risk Analysis

Dividend of 2% is not well covered by earnings or free cash flows

Interest payments are not well covered by earnings


CC Community Fair Values

Create Narrative

See what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.

CC logo
Chemours

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Key Takeaways Growth is driven by strong demand for low-emission refrigerants and advanced materials, with portfolio optimization elevating margins and earnings quality. Industry changes, litigation resolution, and operational improvements position Chemours for stronger market share, pricing power, and sustained cash flow stability.
View narrative
US$16.33
FV
7.3% overvalued intrinsic discount
272
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
CC logo
Chemours

Opteon Refrigerants And Clean Energy Will Revolutionize Material Markets

Key Takeaways Operational improvements and a shift toward specialty products position Chemours for sustained margin gains, free cash flow acceleration, and potential outperformance versus earnings expectations. Regulatory trends, environmental liability resolution, and global electrification could fuel rapid growth across key segments and support premium valuation multiples.
View narrative
US$21
FV
16.5% undervalued intrinsic discount
21
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
CC logo
Chemours

Escalating PFAS Liabilities And Cost Pressures Will Weigh Future Prospects

Key Takeaways Escalating environmental regulations and legacy legal risks threaten Chemours' revenue growth, profit margins, and future cash flow stability. Dependence on a limited product range and industry trends toward alternatives amplify margin pressure and revenue volatility.
View narrative
US$13
FV
34.8% overvalued intrinsic discount
18
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community
UG logo
Upside Gold

An Undervalued 3.3Moz Gold Project in Canada

Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more

View narrative
3.2k
users have viewed this narrative
13users have liked this narrative
0users have commented on this narrative
71users have followed this narrative
CA$5.07
76.5% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
11.75%
Future PE
21.54x
Price in 2031
CA$5.88

The Chemours Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for Chemours
Historical stock prices
Current Share PriceUS$17.53
52 Week HighUS$21.85
52 Week LowUS$9.13
Beta1.56
1 Month Change12.52%
3 Month Change39.79%
1 Year Change24.33%
3 Year Change-48.64%
5 Year Change-34.93%
Change since IPO-12.48%

Recent News & Updates

Chemours: No Rush To Buy The Dip Given Non-AI Pressures (Downgrade)

Feb 23

Recent updates

Chemours: No Rush To Buy The Dip Given Non-AI Pressures (Downgrade)

Feb 23

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Chemours (NYSE:CC) Has No Shortage Of Debt

Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt

We Like The Quality Of Chemours' (NYSE:CC) Earnings

May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Jan 24
Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Jan 08
Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Dec 05
Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Chemours: Hasn't Been A Great Year, But The Long-Term Prospects Look Bright

Nov 21

Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Nov 12
Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Shareholder Returns

CCUS ChemicalsUS Market
7D-2.7%-2.0%-1.2%
1Y24.3%2.2%17.6%

Return vs Industry: CC exceeded the US Chemicals industry which returned 4.8% over the past year.

Return vs Market: CC exceeded the US Market which returned 18.2% over the past year.

Price Volatility

Is CC's price volatile compared to industry and market?
CC volatility
CC Average Weekly Movement9.7%
Chemicals Industry Average Movement6.2%
Market Average Movement6.6%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: CC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CC's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20145,700Denise M. Dignamwww.chemours.com

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names.

The Chemours Company Fundamentals Summary

How do Chemours's earnings and revenue compare to its market cap?
CC fundamental statistics
Market capUS$2.52b
Earnings (TTM)-US$386.00m
Revenue (TTM)US$5.81b
0.5x
P/S Ratio
-6.8x
P/E Ratio

Is CC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CC income statement (TTM)
RevenueUS$5.81b
Cost of RevenueUS$4.90b
Gross ProfitUS$909.00m
Other ExpensesUS$1.30b
Earnings-US$386.00m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.57
Gross Margin15.65%
Net Profit Margin-6.65%
Debt/Equity Ratio1,634.3%

How did CC perform over the long term?

See historical performance and comparison

Dividends

2.0%
Current Dividend Yield
-20%
Payout Ratio

Does CC pay a reliable dividends?

See CC dividend history and benchmarks
When do you need to buy CC by to receive an upcoming dividend?
Chemours dividend dates
Ex Dividend DateFeb 27 2026
Dividend Pay DateMar 13 2026
Days until Ex dividend6 days
Days until Dividend pay date8 days

Does CC pay a reliable dividends?

See CC dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/04 07:20
End of Day Share Price 2026/03/04 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Chemours Company is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays